Einstein Center for Excellence for Clinical Trials in Neuroscience

爱因斯坦神经科学临床试验卓越中心

基本信息

项目摘要

DESCRIPTION (provided by applicant): The overall aim of this proposal is to establish the Einstein College of Medicine (Einstein) and our affiliated delivery systems as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (the Einstein-NEXT). Our affiliated delivery systems include the Montefiore System in the Bronx, the Beth Israel Hospital in Manhattan and the North Shore-Long Island Jewish System in Queens and Long Island. Our faculty of over 150 adult neurologists and 25 pediatric neurologists serve a remarkably diverse population base of over 8 million. Each year, we assess over 35,000 individual neurology patients, including more than 10,000 pediatric neurology patients. Our research infrastructure includes 2 CTSA affiliated Clinical Research Centers (CRCs) and access to excellent staff and many Cores of the CTSA and a third CRC at North Shore. Each delivery system has several Neuroscience Centers of Excellence in particular disease areas with special populations, clinical expertise and research infrastructure, including more than 30 study coordinators. To leverage these extensive resources, we will build on the foundation of the Einstein-Montefiore CTSA with its Office of Clinical Trials and its 2 CRCs. This proposal aims to: Aim 1: Facilitate rapid access to clinical trial resources at Einstein and affiliates. Aim 2: To optimize the rapid evaluation and launch of proposed studies, including development of efficient approaches for identifying, screening and recruiting diverse samples of eligible patients. Aim 3: To optimize patient participation and retention through the application of community outreach and a behavioral intervention theoretical model. Aim 4: To monitor our sites to ensure protocol adherence, maximize data quality and site efficiency through the use of Six Sigma processes. We will achieve these aims through an Oversight Committee which will include the leadership team for the Einstein- NEXT, the Director of the Office of Clinical Trials and clinical trial leaders from each of the sites. For each protocol, we will develop a Study Assessment and Management Team, which will site and staff the study, facilitate recruiting and retention and monitor metrics f success.
描述(由申请人提供):本提案的总体目标是将爱因斯坦医学院(Einstein)及其附属输送系统作为神经科学临床试验卓越网络(Einstein-NEXT)中的临床研究中心。我们的附属输送系统包括布朗克斯的蒙蒂菲奥里系统、曼哈顿的贝斯以色列医院以及皇后区和长岛的北岸长岛犹太系统。我们的150多名成人神经学家和25名儿科神经学家的教师为超过800万的多样化人口提供服务。每年,我们评估超过35,000名神经科患者,包括超过10,000名儿童神经科患者。我们的研究基础设施包括2个CTSA附属的临床研究中心(CRC),并获得优秀的工作人员和CTSA的许多核心,以及北岸的第三个CRC。 每个交付系统在特定疾病领域都有几个神经科学卓越中心,具有特殊人群,临床专业知识和研究基础设施,包括30多名研究协调员。 为了利用这些广泛的资源,我们将建立在Einstein-Montefiore CTSA及其临床试验办公室和2个CRC的基础上。目标1:便利快速获取 爱因斯坦及其附属机构的临床试验资源。目标2:优化快速评价和 启动拟议的研究,包括制定有效的方法,以确定、筛选和招募合格患者的各种样本。目的3:通过社区外展和行为干预理论模型的应用,优化患者的参与和保留。目标4:通过使用六西格玛流程,监控我们的研究中心,以确保方案遵守,最大限度地提高数据质量和研究中心效率。我们将通过监督委员会实现这些目标,该委员会将包括Einstein- NEXT的领导团队、临床试验办公室主任和每个研究中心的临床试验负责人。对于每个方案,我们将建立一个研究评估和管理团队,该团队将负责研究的现场和人员配备,促进招募和保留,并监测成功的指标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard B. LIPTON其他文献

Richard B. LIPTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard B. LIPTON', 18)}}的其他基金

Einstein Aging Study
爱因斯坦衰老研究
  • 批准号:
    10391027
  • 财政年份:
    2021
  • 资助金额:
    $ 33.24万
  • 项目类别:
Migraine Clinical Outcome Assessment System (MiCOAS)
偏头痛临床结果评估系统 (MiCOAS)
  • 批准号:
    10415455
  • 财政年份:
    2019
  • 资助金额:
    $ 33.24万
  • 项目类别:
Migraine Clinical Outcome Assessment System (MiCOAS)
偏头痛临床结果评估系统 (MiCOAS)
  • 批准号:
    10244980
  • 财政年份:
    2019
  • 资助金额:
    $ 33.24万
  • 项目类别:
Migraine Clinical Outcome Assessment System (MiCOAS)
偏头痛临床结果评估系统 (MiCOAS)
  • 批准号:
    10471249
  • 财政年份:
    2019
  • 资助金额:
    $ 33.24万
  • 项目类别:
Einstein Center for Excellence for Clinical Trials in Neuroscience
爱因斯坦神经科学临床试验卓越中心
  • 批准号:
    9857114
  • 财政年份:
    2015
  • 资助金额:
    $ 33.24万
  • 项目类别:
Einstein Center for Excellence for Clinical Trials in Neuroscience
爱因斯坦神经科学临床试验卓越中心
  • 批准号:
    9131491
  • 财政年份:
    2015
  • 资助金额:
    $ 33.24万
  • 项目类别:
Einstein Center for Excellence for Clinical Trials in Neuroscience
爱因斯坦神经科学临床试验卓越中心
  • 批准号:
    8241317
  • 财政年份:
    2011
  • 资助金额:
    $ 33.24万
  • 项目类别:
Einstein Center for Excellence for Clinical Trials in Neuroscience
爱因斯坦神经科学临床试验卓越中心
  • 批准号:
    8729624
  • 财政年份:
    2011
  • 资助金额:
    $ 33.24万
  • 项目类别:
Einstein Center for Excellence for Clinical Trials in Neuroscience
爱因斯坦神经科学临床试验卓越中心
  • 批准号:
    8547116
  • 财政年份:
    2011
  • 资助金额:
    $ 33.24万
  • 项目类别:
Einstein Center for Excellence for Clinical Trials in Neuroscience
爱因斯坦神经科学临床试验卓越中心
  • 批准号:
    8338434
  • 财政年份:
    2011
  • 资助金额:
    $ 33.24万
  • 项目类别:

相似海外基金

Structural Racism, Pharmacy Closures and Disparities in Medication Adherence Among Older Adult Medicare Part-D Beneficiaries
结构性种族主义、药房关闭以及老年人医疗保险 D 部分受益人的药物依从性差异
  • 批准号:
    10568717
  • 财政年份:
    2023
  • 资助金额:
    $ 33.24万
  • 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
  • 批准号:
    10419967
  • 财政年份:
    2022
  • 资助金额:
    $ 33.24万
  • 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
  • 批准号:
    10592441
  • 财政年份:
    2022
  • 资助金额:
    $ 33.24万
  • 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
  • 批准号:
    10369750
  • 财政年份:
    2021
  • 资助金额:
    $ 33.24万
  • 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
  • 批准号:
    10633248
  • 财政年份:
    2021
  • 资助金额:
    $ 33.24万
  • 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
  • 批准号:
    10487516
  • 财政年份:
    2021
  • 资助金额:
    $ 33.24万
  • 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
  • 批准号:
    10228564
  • 财政年份:
    2018
  • 资助金额:
    $ 33.24万
  • 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
  • 批准号:
    9347041
  • 财政年份:
    2017
  • 资助金额:
    $ 33.24万
  • 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
  • 批准号:
    9480702
  • 财政年份:
    2016
  • 资助金额:
    $ 33.24万
  • 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
  • 批准号:
    9906853
  • 财政年份:
    2016
  • 资助金额:
    $ 33.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了